VolitionRx (Singapore)

VolitionRx (Singapore) is the Singapore-based subsidiary of VolitionRx Limited, a multinational epigenetics company focused on advancing the science of epigenetics to diagnose and monitor life-altering diseases. The company describes itself as dedicated to saving lives and improving outcomes for people and animals through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, Volition develops and commercializes simple, easy-to-use, cost-effective blood tests designed to help diagnose and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. The company's core technology is its patented Nucleosomics™ platform, which uses chromosomal structures such as nucleosomes and transcription factors as biomarkers. Its flagship Nu.Q® Platform is a nucleosome quantification technology currently used for cancer applications in veterinary medicine, while the company continues to expand into human medicine through early clinical trials in cancer, sepsis and beyond. Nu.Q® NETs is a CE-marked diagnostic solution that clinicians can use to detect NETosis. Nu.Q® Vet is an affordable veterinary cancer test. The company also markets Nu.Q® Cancer and Nu.Q® Discover product pillars. VolitionRx Limited is a multi-national company with operations spanning several countries, and the Singapore entity forms part of this international structure. The company has a team of over 70 dedicated staff across a wide range of disciplines. Its executive team includes Cameron Reynolds (President & Group Chief Executive Officer), Terig Hughes (Group Chief Financial Officer), Gaetan Michel (Chief Operating Officer), Nick Plummer (Group General Counsel), Louise Batchelor (Group Chief Marketing & Communications Officer), Dr Andrew Retter (Medical Consultant), Jake Micallef (Chief Scientific Officer), Gael Forterre (Chief Licensing Officer), Jasmine Kway (Chief Revenue Officer), and Rod Rootsaert (Corporate Secretary). The board is chaired by Timothy I. Still. Recent corporate activity includes the launch of the DETECSEPS program in France, the pre-payment in full of a $7.5 million promissory note, and the presentation of early Stage I solid cancer detection at the ESMO MAP Conference. The company also announced a collaboration with Sysmex and continues to publish peer-reviewed research on its Capture-Seq™ technology and Nu.Q® NETs platform.

VolitionRx Limited is a multi-national epigenetics company that operates through subsidiaries, including VolitionRx (Singapore). The company's name reflects its purpose: "Volition means to have determination and a purpose." It was founded to advance the science of epigenetics and revolutionize the way disease is diagnosed and monitored. The company's core technology, Nucleosomics™, uses chromosomal structures such as nucleosomes and transcription factors as biomarkers. Its Nu.Q® Platform is a nucleosome quantification technology. Initially, the technology found application in veterinary medicine for cancer detection through Nu.Q® Vet, an affordable test. The company then expanded into human medicine, developing Nu.Q® NETs, a CE-marked diagnostic solution for detecting NETosis, which is associated with sepsis. Nu.Q® Cancer and Nu.Q® Discover are additional product pillars. VolitionRx Limited has a team of over 70 staff across a wide range of disciplines. The company is led by President & Group CEO Cameron Reynolds, with a board chaired by Timothy I. Still. The Singapore entity is part of the group's international structure, which includes operations in multiple countries. Recent developments include the launch of the DETECSEPS program in France, the pre-payment in full of a $7.5 million promissory note, and the presentation of early Stage I solid cancer detection at the ESMO MAP Conference. The company also announced a collaboration with Sysmex and continues to publish peer-reviewed research on its Capture-Seq™ technology and Nu.Q® NETs platform.

• VolitionRx Limited founded as a multinational epigenetics company

• Nu.Q® Vet commercialized for veterinary cancer detection

• Nu.Q® NETs receives CE marking for NETosis detection

• DETECSEPS program launched in France

• Pre-payment in full of $7.5 million promissory note

• Early Stage I solid cancer detection presented at ESMO MAP Conference

• Collaboration with Sysmex announced

A multinational epigenetics company developing simple, cost-effective nucleosome-based blood tests for early detection and monitoring of cancer, sepsis and other diseases.

• Nu.Q® Platform

  Nucleosome quantification technology used for cancer applications in veterinary medicine and expanding into human medicine.

• Nu.Q® NETs

  CE-marked diagnostic solution for detecting NETosis, associated with sepsis.

• Nu.Q® Vet

  Affordable veterinary cancer test.

• Nu.Q® Cancer

  Cancer detection product pillar.

• Nu.Q® Discover

  Product pillar for discovery applications.

• Capture-Seq™

  Technology platform with peer-reviewed publications.

1. 1Volition - Early Diagnosis and Nucleosome Quantificationvolition.com
2. 2Our Company - Volitionvolition.com
3. 3Our Team - Volitionvolition.com
4. 4Resources - Volitionvolition.com
5. 5VolitionRx (Singapore) - Wikidatawikidata.org
6. 6Resources - Volitionvolition.com